Compare SPB & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPB | VERA |
|---|---|---|
| Founded | 1906 | 2016 |
| Country | United States | United States |
| Employees | N/A | 361 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 1994 | 2021 |
| Metric | SPB | VERA |
|---|---|---|
| Price | $78.94 | $27.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | ★ $98.75 | $74.20 |
| AVG Volume (30 Days) | 289.5K | ★ 1.9M |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $3,802,100,000.00 | N/A |
| Revenue This Year | $1.92 | N/A |
| Revenue Next Year | $1.26 | $863.11 |
| P/E Ratio | $78.12 | ★ N/A |
| Revenue Growth | ★ 20.86 | N/A |
| 52 Week Low | $51.41 | $23.05 |
| 52 Week High | $99.06 | $56.05 |
| Indicator | SPB | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 40.34 | 37.96 |
| Support Level | $77.74 | N/A |
| Resistance Level | $80.83 | $36.95 |
| Average True Range (ATR) | 1.97 | 1.37 |
| MACD | 0.16 | -0.27 |
| Stochastic Oscillator | 45.02 | 24.72 |
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, which generates maximum revenue; Global Pet Care; and Home and Garden. The company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific. It generates maximum revenue from North America.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.